Allakos Inc. (ALLK): Price and Financial Metrics
GET POWR RATINGS... FREE!
ALLK Stock Price Chart Interactive Chart >
ALLK Price/Volume Stats
|Current price||$7.44||52-week high||$11.73|
|Prev. close||$7.27||52-week low||$2.54|
|Day high||$7.57||Avg. volume||1,552,763|
|50-day MA||$6.28||Dividend yield||N/A|
|200-day MA||$4.77||Market Cap||633.92M|
Allakos Inc. (ALLK) Company Bio
Allakos Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. The company was founded in 2012 and is based in San Carlos, California.
Most Popular Stories View All
ALLK Latest News Stream
|Loading, please wait...|
ALLK Latest Social Stream
View Full ALLK Social Stream
Latest ALLK News From Around the Web
Below are the latest news stories about ALLAKOS INC that investors may wish to consider to help them evaluate ALLK as an investment opportunity.
Allakos Presents Preclinical Data on AK007, a Siglec-10 Antagonist Antibody, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting
– Siglec-10 is a myeloid checkpoint receptor selectively expressed on tumor associated macrophages and dendritic cells –– AK007 potently blocks all known ligand interaction with Siglec-10, including the “don’t eat me” signal CD24 –– Monotherapy treatment with a Siglec-10 antagonist antibody polarized tumor-associated myeloid cells and reduced tumor burden in pre-clinical studies – SAN CARLOS, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology co
SAN CARLOS, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the third quarter ended September 30, 2022. Recent Allakos Events Allakos’s lirentelimab clinical development is focused on atopic dermatitis and chronic spontaneous urticaria. Initiated a Phase 2b randomized,
Sarissa Capital disclosed a large stake in pharmaceutical firm Alkermes. New Enterprise Associates more than doubled its investment in clinical-stage drug firm Allakos.
Troubled healthcare companies will have much more difficulty surviving, so identifying healthcare stocks to sell is very important.
After losing 95% in the past year, Allakos Inc. (NASDAQ:ALLK) institutional owners must be relieved by the recent gain
A look at the shareholders of Allakos Inc. ( NASDAQ:ALLK ) can tell us which group is most powerful. And the group that...
ALLK Price Returns